Madrigal Pharmaceuticals Inc (MDGL) Company Profile & Statistics

Madrigal Pharmaceuticals Inc
MDGL
(Nasdaq - US)
Closed
329.22
+12.13 (+3.83%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
317.65
High
329.66
Low
314.62

About Madrigal Pharmaceuticals Inc

CEO

William J. Sibold

Headquarters

200 barr harbor drive, suite 200

west conshohocken, pa 19428, united states

Auditor

PricewaterhouseCoopers LLP

Employees

376

Share Holders

Website

www.madrigalpharma.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.

Madrigal Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	7.18B
Enterprise Value	7.06B
Enterprise Value/EBITDA (ttm)	-12.95
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	8.82
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	48.05%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	-302.56%
Return on Equity (ttm)	-71.78%
Return on Invested Capital (ttm)	-64.37%
Return on Assets (ttm)	-53.25%

Income Statement

Revenue (ttm)	76.81M
Revenue Per Share (ttm)	3.52
Gross Profit (ttm)	74.03M
EBITDA (ttm)³	-545.28M
Net Income Avi to Common (ttm)	-518.67M
Diluted EPS (ttm)	-25.08

Share Statistics

Beta (5Y Monthly)	-0.46
52-Week Change	73.23%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	21.81M
Dividend Yield	0.00%
Float ⁴	16.84M
% Held by Insiders	22.80%
% Held by Institutions	98.50%

Balance Sheet

Total Cash (mrq)	1.00B
Total Cash Per Share (mrq)	46.02
Total Debt (mrq)	117.09M
Total Debt/Equity (mrq)	15.07%
Current Ratio (mrq)	5.98%
Quick Ratio (mrq)	5.93%
Book Value Per Share (mrq)	35.64

Cash Flow

Operating Cash Flow Per Share (ytd)	-16.14
Free Cash Flow (ytd)	-352.35M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Madrigal Pharmaceuticals Inc

Trade With A Regulated Broker